Quick Answer
Scinai Immunotherapeutics Ltd. reported R&D Expense of $5.53 million for fiscal year 2024.
Scinai Immunotherapeutics Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $5.53M | +6.2% |
| 2023 | $5.21M | -9.6% |
| 2022 | $5.76M | +77.4% |
| 2021 | $3.25M | -93.7% |
| 2020 | $51.46M | -25.0% |
| 2019 | $68.64M | -4.5% |
| 2018 | $71.91M | +283.0% |
| 2017 | $18.78M | +140.9% |
| 2016 | $7.79M | -1.4% |
| 2015 | $7.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $2.00M | +71.5% | +71.5% |
| March 31, 2022 | $1.16M | — | — |
- Scinai Immunotherapeutics Ltd. showed an increase of +6.2% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, Scinai Immunotherapeutics Ltd.’s r&d expense has declined by 30.0% (from $7.91 million to $5.53 million).
- The most recent figure is from Scinai Immunotherapeutics Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on May 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: